RXi Pharmaceuticals Corporation
257 Simarano Drive, Suite 101
Marlborough, MA 01752
(508)767-3861
April 5, 2018
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
Attn: Jeffrey Gabor
| Re: | RXi Pharmaceuticals Corporation |
| Registration Statement on FormS-3 |
| Filed March 29, 2018 FileNo. 333-224031 |
Ladies and Gentlemen:
Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, RXi Pharmaceuticals Corporation, a Delaware corporation (the “Company”), hereby respectfully requests that the effective time of the above referenced Registration Statement on FormS-3 filed by the Company (the “Registration Statement”) be accelerated to 4:00 p.m., Eastern Daylight Time, on April 6, 2018 or as soon thereafter as practicable.
[Signature page follows]
Very truly yours,
RXi Pharmaceuticals Corporation |
| /s/ Geert Cauwenbergh |
Geert Cauwenbergh President, Chief Executive Officer and acting Chief Financial Officer |
| cc: | Ryan A. Murr, Gibson, Dunn & Crutcher LLP |
